|Dr. Viktor Drvota M.D., Ph.D.||Chief Exec. Officer||4.95M||N/A||1965|
|Mr. Per Aniansson||CFO & Investment Director||N/A||N/A||1966|
|Ms. Eva Montgomerie||Head of Accounting||N/A||N/A||1958|
|Dr. John Öhd M.D., Ph.D.||Chief Scientific Officer & Venture Partner||N/A||N/A||1971|
|Mr. Johan Dighed||Deputy CEO & Gen. Counsel||N/A||N/A||1973|
|Mr. Yan Cheng||Pres Asia||N/A||N/A||1985|
|Ms. Linda Spahiu||Investment Mang.||N/A||N/A||1985|
Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.
Karolinska Development AB (publ)’s ISS Governance QualityScore as of July 31, 2022 is 5. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 7; Compensation: 6.